Immunochemotherapy of visceral leishmaniasis: a pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony.
The clinical, parasitological, hematological, and serological evolution of visceral leishmaniasis in Brazilian patients was assessed during treatment with human recombinant interferon-gamma (rIFN-gamma; 0.1 mg/m2 i.m. days 1-14) followed by pentavalent antimony (Sbv; 10 mg/kg days 22-28). At day 30, 6 patients had improved, 2 had slightly improved, and 1 patient had deteriorated. IFN-gamma was well tolerated in the dose tested and may be very effective as an adjunct to conventional therapy with antimony.
Harms
G
G
Landesinstitut für Tropenmedizin Berlin, Germany.
Zwingenberger
K
K
Sandkamp
B
B
Omena
S
S
Pedrosa
C
C
Richter
J
J
Rosenkaimer
F
F
Feldmeier
H
H
Bienzle
U
U
D000293:Adolescent; D000328:Adult; D000965:Antimony / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D007898:Leishmaniasis, Visceral / Q000628:therapy*; D008297:Male; D010865:Pilot Projects; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D007371:Interferon-gamma; D000965:Antimony